WS #16222
Elevance Health reported a significant earnings beat with Q3 adjusted EPS of $6.99 versus a $4.68 estimate, driven by strong sales and margin expansion. Integra LifeSciences affirmed its full-year guidance, signaling stability in the medical devices sector. These results highlight the resilience of healthcare stocks, which are increasingly viewed as defensive havens in a volatile macro environment characterized by geopolitical tensions and rate uncertainty.
Healthcare Earnings and Defensive Rotation
Elevance Health reported a significant earnings beat with Q3 adjusted EPS of $6.99 versus a $4.68 estimate, driven by strong sales and margin expansion. Integra LifeSciences affirmed its full-year guidance, signaling stability in the medical devices sector. These results highlight the resilience of healthcare stocks, which are increasingly viewed as defensive havens in a volatile macro environment characterized by geopolitical tensions and rate uncertainty.